The A.I. Daily
OpenAI-funded Biossil buys antibiotic degrader portfolio for up to $91M
OpenAI-funded Biossil is acquiring Theriva's unwanted antibiotic degrader portfolio for up to $91M. The figure is a ceiling; detailed terms were not disclosed.